News

FDA announces approval for Orbactiv

BY Ryan Chavis

SILVER SPRING, Md. — The Food and Drug Administration earlier this week announced approval for Orbactiv (oritavancin), an antibacterial drug used to treat patients with acute bacterial skin and skin structure infections. The drug is administered intravenously.

Orbactiv is the third new antibacterial drug approved by the FDA this year to treat ABSSSI. The agency previously announced approval for Dalvance and Sivextro.

“The approval of several new antibacterial drugs this year demonstrates that we are making progress in increasing the availability of treatment options for patients and physicians,” said Edward Cox, M.D., M.P.H, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. “However, more work is needed in this area, and the FDA remains a committed partner to help promote the development of antibacterial drugs.”

Orbactiv is marketed by the Medicines Co.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

NACDS RxImpact hosts 82nd pharmacy tour in 2014

BY Antoinette Alexander

ALEXANDRIA, Va. — Several NACDS chain member companies have conducted Congressional pharmacy tours in recent weeks, bringing the total number of NACDS RxImpact in-district events to 82 for 2014.  

NACDS pharmacy tours are all about educating Congress about the value pharmacy provides and giving legislators and their staff members an inside view about what makes pharmacies such integral, accessible resources in communities.

Among the most recent in-district events, regional director for Rep. Michael McCaul, R-Texas, toured the H-E-B in Katy, Texas, on Aug. 5. The pharmacy team reported that the tour, which lasted over an hour, was "excellent." NACDS RxImpact hosted two additional in-district activities during the week, which brings the total number for 2014 to 82. Rep. Joaquin Castro, D-Texas, toured a San Antonio H-E-B and the district director for Rep. David Schweikert, R-Ariz., toured a Scottsdale, Ariz. Walgreens.

Additional Congressional pharmacy tours include — U.S. Rep. Chris Van Hollen, D-Md, toured a Westminster, Md. Giant; U.S. Rep. Henry Cuellar (pictured above), D-Texas, toured a Lavernia, Texas HEB Pharmacy and U.S. Rep. Lynne Jenkins, R-Kan., a member of the House Ways & Means Committee, met with Hy-Vee at the Jenkins' Topeka, Kan., District Office. Also, the district director for U.S. Rep. Steve Womack, R-Ark., toured a Rogers, Ark., Walmart, the district director for U.S. Rep. Matt Salmon, R-Ariz., toured a Gilbert, Ariz., Walmart, and the deputy district director for U.S. Rep. Steve Southerland, R-Fla., toured a Tallahassee, Fla., Walgreens.

The grassroots advocacy program also posted its 16th and 17th continuing education training sessions as part of the Tennessee Pharmacists Association Annual Meeting. The CE training programs in Tennessee educated pharmacists and students about the power of effective constituent communications to influence the policymaking process.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Roundy’s reports net loss of $13.5 million for Q2

BY Dan Berthiaume

MILWAUKEE — Costs related to the exit of its Rainbow business in the Twin Cities markets, as well as the upcoming closure of a distribution center, helped push Roundy’s to a net loss of $13.5 million in the second quarter of fiscal 2014.

Net income for the quarter was $11.6 million, while net sales from continuing operations for second quarter 2014 were $971.9 million, an increase of 12% from $868.3 million for second quarter 2013. Same-store sales dropped 2.2%.

During the quarter, Roundy’s sold 18 Rainbow stores and closed the remaining nine not included in the sale, incurring an impairment charge. Roundy’s is also closing a distribution facility in Stevens Point, Wisconsin in the third quarter of the fiscal year, which has already incurred some costs.

Roundy’s expects to report net losses per share and negative same-store sales growth for the third quarter and full fiscal year 2013.

"We are confident that the strategic actions we started in the second quarter will improve our cost structure, operational efficiency and overall execution to provide positive long-term benefits to our business," chairman, president and CEO Robert A. Mariano said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?